EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abiomed's enterprise value is $16,360 Mil.
Abiomed's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $282 Mil. Therefore, Abiomed's EV-to-EBITDA for today is 58.08.
The historical rank and industry rank for Abiomed's EV-to-EBITDA or its related term are showing as below:
ABMD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 20.36 Med: 58.01 Max: 180.31
Current: 58.08
During the past 13 years, the highest EV-to-EBITDA of Abiomed was 180.31. The lowest was 20.36. And the median was 58.01.
ABMD's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 16.065
vs ABMD: 58.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-05), Abiomed's stock price is $381.02.
Abiomed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $5.820. Therefore, Abiomed's PE Ratio for today is 65.47.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Abiomed EV-to-EBITDA Historical Data
The historical data trend for Abiomed's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Abiomed's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abiomed's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abiomed's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abiomed's EV-to-EBITDA falls into.
Abiomed EV-to-EBITDA Calculation
Abiomed's EV-to-EBITDA for today is calculated as:
Abiomed's current Enterprise Value is $16,360 Mil.
Abiomed's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $282 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abiomed (NAS:ABMD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Abiomed's share price for today is $381.02.
Abiomed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Abiomed's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABMD has been successfully added to your 